

CLAIMS

1. A polynucleotide having a promoter activity for the polypeptide of SEQ ID NO:2 and comprising a nucleotide sequence consisting of a 3253rd to 5023rd nucleotides in SEQ ID NO:17 or a nucleotide sequence consisting of the 3253rd to the 5023rd nucleotides in SEQ ID NO:17 in which 1 to 10 nucleotides are substituted, deleted, and/or inserted.
2. A polynucleotide according to claim 1, comprising a nucleotide sequence of SEQ ID NO:17 or a nucleotide sequence consisting of a nucleotide sequence of SEQ ID NO:17 in which 1 to 10 nucleotides are substituted, deleted, and/or inserted.
3. A polynucleotide according to claim 1, comprising the nucleotide sequence consisting of the 3253rd to 5023rd nucleotides in SEQ ID NO:17 or the nucleotide sequence of SEQ ID NO:17.
4. An expression vector comprising the polynucleotide according to any one of claims 1 to 3.
5. A cell transfected with the expression vector according to claim 4.

6. A screening tool for a substance for the treatment and/or prevention of chronic renal failure, comprising the polynucleotide according to claim 1 or the cell according to claim 5.

7. Use of the polynucleotide according to claim 1 or the cell according to claim 5 for screening a substance for the treatment and/or prevention of chronic renal failure.

8. A method for analyzing a test compound about whether or not the test compound inhibits the promoter activity of the polynucleotide according to any one of claims 1 to 3, comprising (1) a step of allowing the test compound to contact with the cell according to claim 5 and (2) a step of detecting the promoter activity.

9. A method for screening a substance suppressing the expression of a polypeptide of SEQ ID NO:2, comprising the analyzing step by the method according to claim 8 and a step of selecting a substance inhibiting the promoter activity.

10. A method for screening a substance for the treatment and/or prevention of chronic renal failure by the method according to claim 9.

11. A method for producing a pharmaceutical composition for the treatment and/or prevention of chronic renal failure, comprising the analyzing step by the method according to claim 8 and a formulation step.